SG11201501200XA - Methods for predicting risk of developing hypertension - Google Patents
Methods for predicting risk of developing hypertensionInfo
- Publication number
- SG11201501200XA SG11201501200XA SG11201501200XA SG11201501200XA SG11201501200XA SG 11201501200X A SG11201501200X A SG 11201501200XA SG 11201501200X A SG11201501200X A SG 11201501200XA SG 11201501200X A SG11201501200X A SG 11201501200XA SG 11201501200X A SG11201501200X A SG 11201501200XA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- predicting risk
- developing hypertension
- hypertension
- developing
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/545—IL-1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/321—Arterial hypertension
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261683956P | 2012-08-16 | 2012-08-16 | |
| PCT/US2013/055417 WO2014028875A1 (en) | 2012-08-16 | 2013-08-16 | Methods for predicting risk of developing hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201501200XA true SG11201501200XA (en) | 2015-04-29 |
Family
ID=50100476
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201704311VA SG10201704311VA (en) | 2012-08-16 | 2013-08-16 | Methods for predicting risk of developing hypertension |
| SG11201501200XA SG11201501200XA (en) | 2012-08-16 | 2013-08-16 | Methods for predicting risk of developing hypertension |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201704311VA SG10201704311VA (en) | 2012-08-16 | 2013-08-16 | Methods for predicting risk of developing hypertension |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9523696B2 (en) |
| EP (2) | EP3282258A1 (en) |
| JP (3) | JP6298466B2 (en) |
| CN (2) | CN107478841A (en) |
| AU (2) | AU2013302451B2 (en) |
| CA (1) | CA2882133A1 (en) |
| DK (1) | DK2885641T3 (en) |
| ES (1) | ES2656897T3 (en) |
| HK (3) | HK1250782A1 (en) |
| IN (1) | IN2015DN01259A (en) |
| MX (1) | MX358541B (en) |
| NO (1) | NO2983845T3 (en) |
| PL (1) | PL2885641T3 (en) |
| RU (2) | RU2019107598A (en) |
| SG (2) | SG10201704311VA (en) |
| WO (1) | WO2014028875A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432060B2 (en) | 2000-11-09 | 2008-10-07 | The Brigham And Women's Hospital, Inc. | Methods for diagnosis of cardiovascular disease |
| EP3072978B1 (en) | 2002-05-09 | 2018-07-11 | The Brigham and Women's Hospital, Inc. | 1l1rl-1 as a cardiovascular disease marker |
| ES2529618T3 (en) | 2006-04-24 | 2015-02-23 | Critical Care Diagnostics, Inc. | Mortality prediction and detection of serious diseases |
| PL2482078T3 (en) | 2006-05-01 | 2016-08-31 | Critical Care Diagnostics Inc | Diagnosis of cardiovascular disease |
| PT2827152T (en) | 2008-04-18 | 2016-09-13 | Critical Care Diagnostics Inc | Predicting risk of major adverse cardiac events |
| HUE027760T2 (en) | 2010-04-09 | 2016-11-28 | Critical Care Diagnostics Inc | Soluble human st-2 antibodies and assays |
| US8728742B2 (en) | 2011-03-17 | 2014-05-20 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| PL2734222T3 (en) | 2011-07-18 | 2017-03-31 | Critical Care Diagnostics, Inc. | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
| CA2873896A1 (en) | 2012-05-18 | 2013-11-21 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
| JP6298466B2 (en) | 2012-08-16 | 2018-03-20 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | Method for predicting the risk of developing hypertension |
| MX2015002254A (en) | 2012-08-21 | 2015-05-08 | Critical Care Diagnostics Inc | Multimarker risk stratification. |
| CA3103560C (en) | 2014-09-26 | 2023-01-17 | Somalogic, Inc. | Cardiovascular risk event prediction and uses thereof |
| TWI705976B (en) | 2014-11-10 | 2020-10-01 | 美商建南德克公司 | Anti-interleukin-33 antibodies and uses thereof |
| EP3218515B1 (en) | 2014-11-10 | 2023-04-26 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for il-33-mediated disorders |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| RU2677611C1 (en) * | 2018-04-16 | 2019-01-17 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Method for predicting adverse cardiovascular events for a period of 12 months in patients with chronic heart failure with recurrence of angina after myocardial revascularization |
| US11551817B2 (en) | 2020-01-14 | 2023-01-10 | International Business Machines Corporation | Assessing unreliability of clinical risk prediction |
| KR20220152262A (en) | 2020-03-13 | 2022-11-15 | 제넨테크, 인크. | Anti-interleukin-33 antibodies and uses thereof |
| RU2767266C1 (en) * | 2021-05-27 | 2022-03-17 | Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) | Method for predicting the one-year risk of adverse cardiovascular events in men after decompensation of chronic heart failure with preserved left ventricular ejection fraction and obstructive sleep apnea syndrome |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001218871A1 (en) | 2000-03-21 | 2001-10-03 | Takao Arai | Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same |
| US7432060B2 (en) | 2000-11-09 | 2008-10-07 | The Brigham And Women's Hospital, Inc. | Methods for diagnosis of cardiovascular disease |
| KR20040068544A (en) * | 2001-11-05 | 2004-07-31 | 더 브리검 앤드 우먼즈 하스피털, 인크. | Soluble cd40l (cd154) as a prognostic marker of atherosclerotic diseases |
| EP3072978B1 (en) | 2002-05-09 | 2018-07-11 | The Brigham and Women's Hospital, Inc. | 1l1rl-1 as a cardiovascular disease marker |
| WO2005043123A2 (en) | 2003-10-31 | 2005-05-12 | Queststar Medical, Inc. | System and apparatus for body fluid analysis using surface-textured optical materials |
| AU2005311601B2 (en) * | 2004-12-03 | 2011-12-01 | Rhode Island Hospital | Diagnosis and treatment of Alzheimer's Disease |
| ES2529618T3 (en) | 2006-04-24 | 2015-02-23 | Critical Care Diagnostics, Inc. | Mortality prediction and detection of serious diseases |
| ATE517341T1 (en) | 2006-04-27 | 2011-08-15 | Critical Care Diagnostics Inc | INTERLEUKIN-33 (IL-33) FOR THE DIAGNOSIS AND PREDICTION OF CARDIOVASCULAR DISEASES |
| PL2482078T3 (en) | 2006-05-01 | 2016-08-31 | Critical Care Diagnostics Inc | Diagnosis of cardiovascular disease |
| EP2019965B1 (en) | 2006-05-02 | 2015-04-15 | Critical Care Diagnostics, Inc. | Differential diagnosis between pulmonary and cardiovascular disease |
| US8147817B2 (en) * | 2006-05-04 | 2012-04-03 | The Brigham And Women's Hospital, Inc. | IL-33 in the treatment and diagnosis of diseases and disorders |
| GB0703514D0 (en) * | 2007-02-23 | 2007-04-04 | Univ Ulster | Use of riboflavin |
| US20080300798A1 (en) | 2007-04-16 | 2008-12-04 | Mcdevitt John T | Cardibioindex/cardibioscore and utility of salivary proteome in cardiovascular diagnostics |
| ES2401703T3 (en) * | 2007-08-03 | 2013-04-23 | B.R.A.H.M.S Gmbh | Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a non-infectious primary disease |
| PT2827152T (en) | 2008-04-18 | 2016-09-13 | Critical Care Diagnostics Inc | Predicting risk of major adverse cardiac events |
| ES2795003T3 (en) | 2008-10-07 | 2020-11-20 | Brahms Gmbh | Biomarker for the prediction of the first adverse events |
| EP2470910B1 (en) | 2009-08-28 | 2017-01-11 | B.R.A.H.M.S GmbH | Procalcitonin for the prognosis of adverse events |
| HUE027760T2 (en) | 2010-04-09 | 2016-11-28 | Critical Care Diagnostics Inc | Soluble human st-2 antibodies and assays |
| GB201013151D0 (en) * | 2010-08-04 | 2010-09-22 | Isis Innovation | Diagnostic method |
| US8728742B2 (en) | 2011-03-17 | 2014-05-20 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| PL2734222T3 (en) * | 2011-07-18 | 2017-03-31 | Critical Care Diagnostics, Inc. | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
| US20130157290A1 (en) * | 2011-12-16 | 2013-06-20 | Yves Levy | Soluble st2 as a marker for disease |
| CA2873896A1 (en) * | 2012-05-18 | 2013-11-21 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
| JP6298466B2 (en) | 2012-08-16 | 2018-03-20 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | Method for predicting the risk of developing hypertension |
| MX2015002254A (en) | 2012-08-21 | 2015-05-08 | Critical Care Diagnostics Inc | Multimarker risk stratification. |
| CA2935958A1 (en) | 2014-01-10 | 2015-07-16 | Critical Care Diagnostics, Inc. | Methods and systems for determining risk of heart failure |
| USD770057S1 (en) | 2014-04-14 | 2016-10-25 | Critical Care Diagnostics, Inc. | Blood test kit |
| USD800332S1 (en) * | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
| USD800333S1 (en) * | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
-
2013
- 2013-08-16 JP JP2015527668A patent/JP6298466B2/en not_active Expired - Fee Related
- 2013-08-16 SG SG10201704311VA patent/SG10201704311VA/en unknown
- 2013-08-16 PL PL13830006T patent/PL2885641T3/en unknown
- 2013-08-16 CN CN201710532173.1A patent/CN107478841A/en active Pending
- 2013-08-16 CN CN201380052763.4A patent/CN104737023B/en not_active Expired - Fee Related
- 2013-08-16 MX MX2015002061A patent/MX358541B/en active IP Right Grant
- 2013-08-16 SG SG11201501200XA patent/SG11201501200XA/en unknown
- 2013-08-16 US US13/969,116 patent/US9523696B2/en active Active
- 2013-08-16 EP EP17191053.2A patent/EP3282258A1/en not_active Withdrawn
- 2013-08-16 WO PCT/US2013/055417 patent/WO2014028875A1/en active Application Filing
- 2013-08-16 EP EP13830006.6A patent/EP2885641B1/en not_active Not-in-force
- 2013-08-16 ES ES13830006.6T patent/ES2656897T3/en active Active
- 2013-08-16 CA CA2882133A patent/CA2882133A1/en not_active Abandoned
- 2013-08-16 RU RU2019107598A patent/RU2019107598A/en unknown
- 2013-08-16 RU RU2015108959A patent/RU2683026C2/en active
- 2013-08-16 AU AU2013302451A patent/AU2013302451B2/en not_active Ceased
- 2013-08-16 DK DK13830006.6T patent/DK2885641T3/en active
-
2014
- 2014-04-10 NO NO14716337A patent/NO2983845T3/no unknown
-
2015
- 2015-02-16 IN IN1259DEN2015 patent/IN2015DN01259A/en unknown
- 2015-09-08 HK HK18110132.8A patent/HK1250782A1/en unknown
- 2015-09-08 HK HK15108725.8A patent/HK1208075A1/en not_active IP Right Cessation
- 2015-12-23 HK HK15112622.4A patent/HK1212022A1/en not_active IP Right Cessation
-
2016
- 2016-12-19 US US15/382,810 patent/US10041957B2/en not_active Expired - Fee Related
-
2018
- 2018-02-23 JP JP2018030232A patent/JP6757757B2/en not_active Expired - Fee Related
- 2018-08-03 US US16/054,378 patent/US20180335437A1/en not_active Abandoned
-
2019
- 2019-04-15 AU AU2019202597A patent/AU2019202597A1/en not_active Abandoned
-
2020
- 2020-08-31 JP JP2020145790A patent/JP2020196757A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1212022A1 (en) | Methods for predicting risk of developing hypertension | |
| GB201102014D0 (en) | Method for predicting risk of developing cancer | |
| HK1201815A1 (en) | Method for predicting quality or manufacturing condition of cement | |
| EP2686689A4 (en) | Methods predicting risk of an adverse clinical outcome | |
| EP2702513A4 (en) | Determination of recommendation data | |
| EP2794330A4 (en) | Method and module for determining of at least one reference value | |
| EP2817630A4 (en) | Methods for predicting anti-cancer response | |
| RS58967B1 (en) | Method of assessing risk of pml | |
| EP2998740A4 (en) | Method for predicting clinical effect of immunotherapy | |
| EP2786130A4 (en) | Techniques for quantification of samples | |
| EP2699699A4 (en) | Method of diagnosing cancer | |
| EP2857521A4 (en) | Method for assessing endometriosis | |
| GB2510539B (en) | Biomarkers of cancer | |
| AP2014007806A0 (en) | Method for floating | |
| SG11201502998UA (en) | Methods and kits for increasing or predicting oil yield | |
| EP2780766A4 (en) | Devices for quantifying the passage of time | |
| GB201215942D0 (en) | Method of treatent | |
| ZA201400950B (en) | Method for predicting risk of hypertension associated with anti-angiogenesis therapy | |
| HK1204009A1 (en) | Method of determining teratogenic risk | |
| EP2798353A4 (en) | Method for detection of binding | |
| EP2748614A4 (en) | Method of screening for chaperonin modulator | |
| ZA201503833B (en) | Method of hemoglobin-f determination | |
| EP2598881A4 (en) | Methods for predicting risk of stroke | |
| GB201118778D0 (en) | Biomarker method | |
| GB201212279D0 (en) | Method of construction |